Please login to the form below

Not currently logged in
Email:
Password:

Onconova appoints Ajay Bansal as chief financial officer

He joins from Complete Genomics

Ajay Bansal Onconova TherapeuticsAjay Bansal has left Complete Genomics to join cancer specialists Onconova Therapeutics as chief financial officer and president

Bansal (pictured) served as chief financial officer at Complete Genomics since May 2010, having previously held the role of chief financial officer and executive VP of business development at Lexicon Therapeutics.

He joins US-based Onconova as the company prepares to complete enrolment for a phase III study to investigate lead drug candidate rigosertib in patients with myelodysplastic syndromes.

“The potential benefit of rigosertib for the treatment of patients with both solid and haematological malignancies presents a significant opportunity, and I look forward to helping the company meet its objectives for this compound and the rest of the pipeline,” said Bansal.

In addition to his prior roles at Complete Genomics and Lexicon, Bansal has also served as chief financial officer at Nektar Therapuetics and Tercica, later acquired by Ipsen.

8th April 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients
A holistic view of how to work with patients virtually...
The concordance conundrum: the value of improving patient experience
This is the first in a series of articles where we explore how the current climate presents companies with a multitude of opportunities to improve communication between healthcare organisations and...

Infographics